Paclitaxel is a natural anticancer drug,which has been widely used in clinical treatment of breast cancer,ovarian cancer and some head and neck cancer and lung cancer.In recent years,with the growth of the earth’s population and the incidence of cancer,the demand for paclitaxel apis is also increasing.
At present,there are two main sources of paclitaxel apis on the market:one is Taxol extracted from the bark of purple(Taxus taxus),and the other is Docetaxel obtained by semi-synthetic methods.The direct extraction of paclitaxel from yew bark is considered to be an”unsustainable use of resources”,so the international market is now supplied with more paclitaxel apis.In this regard,the export quantity of our country is also increasing year by year.
New uses of paclitaxel apis,such as for the manufacture of eluting vascular stents,have become best-selling products in the international interventional medical device market.This trend is expected to further increase the demand and competition for paclitaxel apis in the international pharmaceutical industry.
However,the production of paclitaxel apis also faces some challenges.First,its production costs are rising,which may put pressure on the development of the paclitaxel industry.Secondly,the production of paclitaxel is greatly affected by environmental,climate and other factors,which may lead to fluctuations in its yield and quality.Therefore,how to reduce the production cost while ensuring the quality and supply stability of paclitaxel API is an important issue that the paclitaxel industry needs to solve.
In summary,as an important part of the anti-cancer drug market,the demand and competition for paclitaxel apis will continue to grow.However,issues such as production cost and output stability also need to be paid attention to and solved.These hot topics will continue to affect the market and industry development of paclitaxel apis.
Note:The potential benefits and applications presented in this article are derived from the published literature.
Post time: Feb-21-2024